CTOs on the Move


 
bioVIGIL headquartered in Las Vegas, Nevada, is a leading provider of healthcare infection control and disease mitigation solutions that enhance the patient care environment improving patient safety, healthcare quality, and hospital bottom lines.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

MDR

MDR LLC. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Etowah Landing Care

Etowah Landing is a post-acute care facility that provides a custom-tailored, medically driven rehabilitation program for fast recovery.

Great Plains Health Alliance

Great Plains Health Alliance, Inc. is a Phillipsburg, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blackline Marketing

Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.